+

US20060159682A1 - Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof - Google Patents

Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof Download PDF

Info

Publication number
US20060159682A1
US20060159682A1 US10/942,929 US94292904A US2006159682A1 US 20060159682 A1 US20060159682 A1 US 20060159682A1 US 94292904 A US94292904 A US 94292904A US 2006159682 A1 US2006159682 A1 US 2006159682A1
Authority
US
United States
Prior art keywords
antibody
mab
mabs
monoclonal antibody
regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/942,929
Inventor
Klaus Bosslet
Gerhard Seemann
Hans Sedlacek
Bernhard Auerbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to US10/942,929 priority Critical patent/US20060159682A1/en
Publication of US20060159682A1 publication Critical patent/US20060159682A1/en
Priority to US12/068,545 priority patent/US7662383B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens.
  • MAbs murine monoclonal antibodies
  • A, B, C and D murine monoclonal antibodies
  • the nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions ⁇ CDR) into a human MAb framework.
  • Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
  • MAb A reacts with antigen 2
  • MAb B reacts with antigen 11
  • MAb C reacts with antigen 7, all of which are described in EP-A2 0,141,079 and are membrane-associated antigens on permanent human tumor cells lines such as the CaLu-1, Chago, Oat 75, PaTu II and Bewo cell line.
  • MAb D is directed against a Vibrio cholerae neuraminidase (VCN)-sensitive epitope on the ganglioside GD 2 which is exposed on human melanoma cell lines.
  • VCN Vibrio cholerae neuraminidase
  • MAbs A to D were generated as described in EP-A2 0,141,079 and isolated by standard methods.
  • MAb B binds to virtually all carcinomas of the gastrointestinal tract and to some ovarian carcinomas and adenocarcinomas of the lung, whereas it does not react with most normal human tissues or reacts only with secretion-containing sites thereon.
  • the binding characteristics are summarized in Table 2.
  • MAb C shows a distinct reaction with 70-80% of stage I and II primary tumors of carcinoma of the pancreas (11/14). Like the primary tumors, most grade I and II metastases of carcinoma of the pancreas appear to have a positive reaction (3/4). The type of reaction on these positive tissues indicates that the epitope recognized by MAb C is located in the cytoplasm, on the membrane and in the intercellular space.
  • Grade III carcinomas of the pancreas do not express the epitope (primary tumor 0/2, metastases 0/5). However, since grade I and II carcinomas of the pancreas comprise up to 95% of carcinomas of the pancreas, MAb C ought to react with 60-70% of all carcinomas of the pancreas.
  • MAb C Another important property of MAb C in its reactivity with the duct system in the chronically inflamed pancreas (pancreatitis 10/13), whereas there is no detectable binding to healthy exocrine and endocrine pancreatic tissue (0/8). Only a minority of the investigated primary tumors of carcinoma of the colon was reactive (4/14), whereas most of the liver metastases of carcinoma of the colon showed distinct binding (7/10).
  • MAb C cross-reactivities of MAb C are confined to the mucus-producing goblet cells of the colonic mucosa and of the stomach. All the other normal tissue tested, including peripheral blood leukocytes and bone marrow, do not express the mucus-associated epitope recognized by MAb C (see Table 3).
  • MAb C recognizes an epitope located on a tumor associated antigen which can be detected at increased levels in patients with gastrointestinal tumors e.g. carcinomas of the pancreas and thus may be used as a tumor marker.
  • MAb D recognizes a VCN-sensitive epitope on the ganglioside GD 2 which does not occur on other bovine cerebral gangliosides, including GD 3 , GM 3 , GM 1 , GT 1a , GD 1b , GD 1a and GM 4 .
  • GD 3 , GM 3 , GM 1 , GT 1a , GD 1b , GD 1a and GM 4 Using MAb D it was possible to stain all gliomas, meningiomas and neurilemmomas in normal human cerebral tissue.
  • Table 4 summarizes the binding properties of MAb D with respect to intracranial tumors.
  • MAb D is suitable for differential diagnosis of neuroblastomas and small round-cell tumors in children.
  • MAb D for two other tumors derived from the neuroectoderm, namely melanomas and small-cell carcinomas of the lung (SCLC), and for unrelated tumors is shown in Table 6.
  • Table 6 Number of tumors Positive Total number melanoma 4* 10 SCLC 2* 11 carcinomas of the colon 0 3 carcinomas of the breast 0 3 non-SCLC: adenocarcinomas 0 3 squamous cell carcinomas of the lung 0 3 large-cell carcinomas 0 3 *Weak and heterogeneous staining of a few tumor cells
  • the immunoglobulin V genes of MAb A to MAb D were isolated using the methods detailed in the Examples.
  • the invention relates to the epitopes specified by MAbs A, B, C and D, monoclonal antibodies against these epitopes, with MAbs A, B, C and D being particularly preferred, and monoclonal antibodies which contain the V genes specified above, or parts thereof (complementarity determining regions), with a human antibody framework or framework parts being preferred.
  • the invention furthermore relates to constructs which contain these V genes or parts thereof together with enzymes or radioactive labels or toxins or catalytic antibodies or combinations of various V-gene specificities or MHC class I or class II antigens or cytolytic components.
  • the invention relates to pharmaceuticals containing the MAb's specified above and the use of said MAb's for in vivo or in vitro diagnosis.
  • FIG. 1 shows the detection of different antigens by MAb C.
  • FIG. 2 shows competition between CA 19-9, C50 and MAb C.
  • CA 19-9 refers to MAb CA 19-9.
  • FIG. 3 shows the nucleotide and protein sequences for the immunoglobulin V genes of MAb A.
  • FIG. 5 shows the nucleotide and protein sequences for the immunoglobulin V genes of MAb C.
  • FIG. 6 shows the nucleotide and protein sequences for the immunoglobulin V genes of MAb D.
  • PCR polymerase chain reaction
  • RNA was prepared from about 3 ⁇ 10 8 cells of the particular hybridomas which secrete MAb A, B, C or D, and poly A + mRNA was enriched from the latter using oligo dT Sepharose.
  • the poly A + mRNA was used for the cDNA synthesis.
  • the first strands of cDNA were synthesized using oligonucleotide primers which hybridize in the J region of the V H nucleotide sequences (oligonucleotide I) and at the 5′ end of the kappa C gene nucleotide sequences (oligonucleotide II).
  • RNA is then decomposed by NaOH treatment.
  • the second strands of cDNA were synthesized using oligonucleotide primers which hybridize at the 5′ ends of the V H (oligonucleotide III) and of the V kappa (oligonucleotide IV) nucleotide sequences.
  • the DNA generated as described in 2. was amplified using oligonucleotides I, III, IV and V (oligonucleotide V hybridizes in the J region of the V kappa nucleotide sequences) and the Taq DNA polymerase from Thermophilus aquatius .
  • a typical mixture contained in 50 ll total volume 5 ll of ds DNA (prepared in 2.), 25 pmol of amplimers, and was 250 lM in each of dATP, dTTP, dCTP and dGTP, 67 mM tris-HCl pH 8.8, 17 mM (NH 4 ) 2 SO 4 , 10 mM MgCl 2 , 200 lg/ml gelatin and 2 units of Taq polymerase.
  • a layer of liquid paraffin was placed on the mixture and then 25 cycles each of 1 min at 95° C. (for denaturation), 1 min at 30° C. (hybridization) and 2 min at 72° C. (DNA synthesis) were carried out using a Techne PHC-1 programmable heating block.
  • the oligonucleotides used for the cDNA cloning and amplification contain restriction cleavage sites.
  • the cDNA cloning and the amplification resulted in these restriction cleavage sites being introduced at the 5′ end and at the 3′ end of the V H and V kappa nucleotide sequences (Pst I and BstE II in V B and Pvu II and Bgl II in V kappa ).
  • the absorbance values determined as shown above correspond to the concentration of the antigen(s) in the samples.
  • concentration of the antigen defined by the specific binding of MAb C, in serum or plasma of tumor patients is significantly elevated as compared to said concentration of healthy control persons or patients with benign disease. This is especially true for patients with carcinoma of the pancreas (FIG. 1 ), significantly elevated concentrations were also determined in serum or plasma of patients with carcinoma of the stomach, colon or rectum. Equally good results were obtained irrespective of the conjugate system (antibody-peroxidase or WGA-peroxidase). With the use of MAb C as specific binding-component a sensitive test for tumor markers of especially gastrointestinal tumor disease can be made.
  • the additional dilution of the standard-antigen after addition of the PBS-solution reduces the signal of the highest standard even without addition of MAb. No further reduction of the signal results by the presence of MAb C in the assay. In contrast hereto the signal formation is totally inhibited by MAb C 50, which as is known, binds among others specifically to the epitope “sialosyl Le a ” recognized also by MAb 19-9: From the above one may conclude that MAb C recognizes a different epitope as MAb 19-9.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions ═CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.

Description

  • This is a continuation of application Ser. No. 08/356,791, filed Dec. 13, 1994; which is a continuation of application Ser. No. 08/118,788, filed Sep. 9, 1993, abandoned; which is a continuation of application Ser. No. 07/949,359, filed Sep. 23, 1992, abandoned; which is a continuation of application Ser. No. 07/497,201, filed Mar. 22, 1990, abandoned; which claims priority to German application P 3909799.4, filed Mar. 24, 1989, all of which are incorporated herein by reference.
  • The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions ═CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
  • MAb A reacts with antigen 2, MAb B reacts with antigen 11 and MAb C reacts with antigen 7, all of which are described in EP-A2 0,141,079 and are membrane-associated antigens on permanent human tumor cells lines such as the CaLu-1, Chago, Oat 75, PaTu II and Bewo cell line. MAb D is directed against a Vibrio cholerae neuraminidase (VCN)-sensitive epitope on the ganglioside GD2 which is exposed on human melanoma cell lines.
  • MAbs A to D were generated as described in EP-A2 0,141,079 and isolated by standard methods.
  • MAb A binds to cells of the granulocyte compartment and to carcinomas of the colon, pancreas and some of the lung and breast, as shown in Table 1.
    TABLE 1
    Binding characteristics of MAb A
    Malignant tissue samples Number of Total
    investigated positives number
    colorectal carcinomas:
    primary carcinomas 6 6
    liver metastases 15 16
    carcinomas of the pancreas 6 8
    carcinomas of the lung:
    small-cell 1 2
    adeno 9 10
    squamous cell 3 4
    large-cell 1 2
    carcinoma of the breast 1 3
  • MAb B binds to virtually all carcinomas of the gastrointestinal tract and to some ovarian carcinomas and adenocarcinomas of the lung, whereas it does not react with most normal human tissues or reacts only with secretion-containing sites thereon. The binding characteristics are summarized in Table 2.
    TABLE 2
    Binding characteristics of MAb B
    Malignant tissue samples Number of Total
    investigated positives number
    colorectal carcinomas:
    primary 6 6
    liver metastases 9 10
    carcinomas of the pancreas 5 6
    carcinomas of the stomach 4 4
    carcinomas of the lung:
    small-cell 2 11
    adeno 9 10
    squamous cell 2 12
    large-cell  4* 12
    carcinoma of the breast 2 9
    ovarian carcinomas 4 6
    (secretion-containing sites)
    carcinomas of the kidneys 1 12

    *weak, heterogeneous reaction
  • MAb C shows a distinct reaction with 70-80% of stage I and II primary tumors of carcinoma of the pancreas (11/14). Like the primary tumors, most grade I and II metastases of carcinoma of the pancreas appear to have a positive reaction (3/4). The type of reaction on these positive tissues indicates that the epitope recognized by MAb C is located in the cytoplasm, on the membrane and in the intercellular space.
  • Grade III carcinomas of the pancreas do not express the epitope (primary tumor 0/2, metastases 0/5). However, since grade I and II carcinomas of the pancreas comprise up to 95% of carcinomas of the pancreas, MAb C ought to react with 60-70% of all carcinomas of the pancreas.
  • Another important property of MAb C in its reactivity with the duct system in the chronically inflamed pancreas (pancreatitis 10/13), whereas there is no detectable binding to healthy exocrine and endocrine pancreatic tissue (0/8). Only a minority of the investigated primary tumors of carcinoma of the colon was reactive (4/14), whereas most of the liver metastases of carcinoma of the colon showed distinct binding (7/10).
  • Cross-reactivities of MAb C are confined to the mucus-producing goblet cells of the colonic mucosa and of the stomach. All the other normal tissue tested, including peripheral blood leukocytes and bone marrow, do not express the mucus-associated epitope recognized by MAb C (see Table 3). MAb C recognizes an epitope located on a tumor associated antigen which can be detected at increased levels in patients with gastrointestinal tumors e.g. carcinomas of the pancreas and thus may be used as a tumor marker.
    TABLE 3
    Summary of the formaldehyde-fixed, paraffin-embedded human
    tissue investigated (indirect immunoperoxidase) with MAb C.
    Grade I/II Grade III
    Pancreatic tumors
    primary carcinoma 11/14 0/2
    liver metastases of carcinoma 3/4 0/5
    papillary carcinoma 1/2
    cystadenoma 0/1
    Pancreatic tissue
    ducts with changes due to pancreatitis 10/13
    normal exo- and endocrine pancreas 0/8
    Carcinomas of the colon
    primary tumors  4/14
    liver metastases  7/10
    Normal colonic tissue
    goblet cells of the mucosa, luminal part  9/10
    part of the mucosa facing the muscularis  3/10
    muscularis mucosae 0/7
    tunica muscularis 0/7
    submucosa 0/7
    Carcinomas of the lung  8/18
    (a few tumor cells)
    Carcinomas of the breast 0/3
    Other normal tissue investigated
    lung 0/3
    liver 0/5
    breast 0/1
    Stomach muscle 0/2
    mucus-prod. cells 3/3
    kidney 0/5
    lymph nodes 0/4
    spleen 0/2
    bone marrow 0/1
    peripheral blood leukocytes 0/2
    connective tissue 0/2
    muscles  0/10
  • MAb D recognizes a VCN-sensitive epitope on the ganglioside GD2 which does not occur on other bovine cerebral gangliosides, including GD3, GM3, GM1, GT1a, GD1b, GD1a and GM4. Using MAb D it was possible to stain all gliomas, meningiomas and neurilemmomas in normal human cerebral tissue. Table 4 summarizes the binding properties of MAb D with respect to intracranial tumors.
    TABLE 4
    Number of tumors
    Type of tumor Positive Total number
    well-differentiated gliomas, grade I-II 6 6
    malignant gliomas, grade III-IV 10 10
    meningiomas 11 11
    neurilemmomas 4 4
    pineal adenomas 0 5
    metastases of carcinomas 0 1
  • The epitope defined by MAb D is also present on neuroblastomas, ganglioneuroblastomas and ganglioneuromas. Table 5 shows a summary.
    TABLE 5
    Reactivity of MAb D with neuroblastomas and
    small round-cell tumors in children
    Number of tumors
    Neuroblastomas Positive Total number
    Grade I 1 1
    Grade II 6 6
    Grade III 4 4
    ganglioneuroblastomas  3xx 3
    Ewing sarcomas 0 2
    rhabdomyosarcomas 0 1
    non-Hodgkin lymphomas   2xxx 5

    x Hughes classification

    xxganglion cells

    xxxsome positive tumor cells
  • Thus, MAb D is suitable for differential diagnosis of neuroblastomas and small round-cell tumors in children.
  • The specificity of MAb D for two other tumors derived from the neuroectoderm, namely melanomas and small-cell carcinomas of the lung (SCLC), and for unrelated tumors is shown in Table 6.
    TABLE 6
    Number of tumors
    Positive Total number
    melanoma  4* 10
    SCLC  2* 11
    carcinomas of the colon 0 3
    carcinomas of the breast 0 3
    non-SCLC:
    adenocarcinomas 0 3
    squamous cell carcinomas of the lung 0 3
    large-cell carcinomas 0 3

    *Weak and heterogeneous staining of a few tumor cells
  • The immunoglobulin V genes of MAb A to MAb D were isolated using the methods detailed in the Examples.
  • The nucleotide and protein sequences are shown in FIG. 3 (V gene of MAb A), FIG. 4 (V gene of MAb B), FIG. 5 (V gene of MAb C) and FIG. 6 (V gene of MAb D). The CDRs can be identified therein as described by Kabat and Wu (loc. cit., see Examples).
  • Accordingly, the invention relates to the epitopes specified by MAbs A, B, C and D, monoclonal antibodies against these epitopes, with MAbs A, B, C and D being particularly preferred, and monoclonal antibodies which contain the V genes specified above, or parts thereof (complementarity determining regions), with a human antibody framework or framework parts being preferred. The invention furthermore relates to constructs which contain these V genes or parts thereof together with enzymes or radioactive labels or toxins or catalytic antibodies or combinations of various V-gene specificities or MHC class I or class II antigens or cytolytic components. Finally, the invention relates to pharmaceuticals containing the MAb's specified above and the use of said MAb's for in vivo or in vitro diagnosis.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the detection of different antigens by MAb C. NS signifies serum samples of healthy blood donors (n=141); AP means serum samples of patients with acute pancreatitis (n=56). CP means serum samples of patients with chronic pancreatitis (n=40) and Pan-Ca means patients with carcinoma of the pancreas (n=82).
  • FIG. 2 shows competition between CA 19-9, C50 and MAb C. CA 19-9 refers to MAb CA 19-9.
  • FIG. 3 shows the nucleotide and protein sequences for the immunoglobulin V genes of MAb A.
  • FIG. 4 shows the nucleotide and protein sequences for the immunoglobulin V genes of MAb B.
  • FIG. 5 shows the nucleotide and protein sequences for the immunoglobulin V genes of MAb C.
  • FIG. 6 shows the nucleotide and protein sequences for the immunoglobulin V genes of MAb D.
  • The invention is furthermore contained in the Examples and the patent claims.
    • EXAMPLES
  • The polymerase chain reaction (PCR) described by Saiki et al., Science 230,1350-1354 (1985) was employed hereinafter for the cloning and expression of the variable domain of murine immunoglobulins (Ig).
  • 1. Identification of the Conserved Regions at the 5′ and 3′ end of the Murine Heavy Ig Chain (VH) and the Light Ig Chain (VK).
  • The mutually aligned sequences of the variable regions were taken from the data file of Kabat et al. Sequences of Proteins of Immunological Interest, US Dept. of Health and Human Services, US Government Printing Office (1987). The nucleotide sequences start there at the amino terminus of the mature protein and do not include the signal sequences. Computer screening (DBUTIL, R. Staden (1986) Nucleic Acids Res. 14, 217-231) was used to find suitable primers for cDNA synthesis and amplimers for use in the PCR:
    Oligonucleotide I:
                   BstE II              VH1FORWARD
    5′ TGA GGA GAC GGT GAC CGT GGT CCC TTG GCC CCA 3′
    Oligonucleotide II:
             CK1
    5′ TGC AGC ATC AGCC 3′
    Oligonucleotide III:
    5′ AG GTC CAG CTG CAG GAG TCT GG 3′
            G A A         C     A
                  PstI
                     VH1 BACKWARD
    Oligonucleotide IV:
    5′ GAC ATT CAG CTG ACC CAG TCT CCA 3′
               PvuII
                        VK1 BACKWARD
    Oligonucleotide V:
        VK1 FORWARD
    5′ GTT AGA TCT CCA GCT TGG TCC C 3′
           Bgl II
  • 2. cDNA Synthesis
  • RNA was prepared from about 3×108 cells of the particular hybridomas which secrete MAb A, B, C or D, and poly A+ mRNA was enriched from the latter using oligo dT Sepharose. The poly A+ mRNA was used for the cDNA synthesis. The first strands of cDNA were synthesized using oligonucleotide primers which hybridize in the J region of the VH nucleotide sequences (oligonucleotide I) and at the 5′ end of the kappa C gene nucleotide sequences (oligonucleotide II).
  • The RNA is then decomposed by NaOH treatment. The second strands of cDNA were synthesized using oligonucleotide primers which hybridize at the 5′ ends of the VH (oligonucleotide III) and of the Vkappa (oligonucleotide IV) nucleotide sequences.
  • 3. Amplification of the Synthesized cDNA and Sequencing of the Variable Domains
  • The DNA generated as described in 2. was amplified using oligonucleotides I, III, IV and V (oligonucleotide V hybridizes in the J region of the Vkappa nucleotide sequences) and the Taq DNA polymerase from Thermophilus aquatius. A typical mixture contained in 50 ll total volume 5 ll of ds DNA (prepared in 2.), 25 pmol of amplimers, and was 250 lM in each of dATP, dTTP, dCTP and dGTP, 67 mM tris-HCl pH 8.8, 17 mM (NH4)2SO4, 10 mM MgCl2, 200 lg/ml gelatin and 2 units of Taq polymerase. A layer of liquid paraffin was placed on the mixture and then 25 cycles each of 1 min at 95° C. (for denaturation), 1 min at 30° C. (hybridization) and 2 min at 72° C. (DNA synthesis) were carried out using a Techne PHC-1 programmable heating block.
  • The oligonucleotides used for the cDNA cloning and amplification contain restriction cleavage sites. The cDNA cloning and the amplification resulted in these restriction cleavage sites being introduced at the 5′ end and at the 3′ end of the VH and Vkappa nucleotide sequences (Pst I and BstE II in VB and Pvu II and Bgl II in Vkappa).
  • These restriction cleavage sites were then used to clone VH and VK cDNA fragments in M13 vectors (Lys 19, Lys 17) (Verhoyen et al. Science 239, (1988), 1534-1536).
  • Finally, the nucleotide sequences of the particular VH and Vkappa cDNA fragments were determined using the method of Sanger (PNAS, USA, 74, 5463-5467, (1977)) from the Lys 19 and Lys 17 vectors (see FIGS. 3-6).
  • Examples 4 and 5 explain the use of the MAb C described using MAb C:
    • Example 4
  • MAb C was fixed to the wells of microtitration plates (Nunc) by adsorption. Into these wells 20 μl sample plus 100 μl buffer-solution (OSND, Behringwerke AG) each was pipetted and 2 respective 3 hours incubated. After threefold washing with diluted Enzygnost® washing solution (OSEN, Behringwerke AG) 100 μl conjugate-solution was filled into each well. Used here were conjugates of peroxidase with lectin (e.g. wheat germ agglutinin {circumflex over (=)}WGA) or with other antibodies recognizing different epitopes of the tumor-associated antigens defined by MAb C. The following two or three hours incubation step at 37° C. was terminated by 3 wash cycles. For the third incubation step at room temperature 100 μl each of a buffer/substrate-chromogene solution (OUVG/OUSF Behringwerke AG) was filled into the wells and the enzyme reaction was terminated after 30 min. with 100 μl of stopping solution Enzygnost® (OSFA, Behringwerke AG). Absorbance of the samples was measured at 450 nm.
  • Result:
  • The absorbance values determined as shown above correspond to the concentration of the antigen(s) in the samples. The concentration of the antigen defined by the specific binding of MAb C, in serum or plasma of tumor patients is significantly elevated as compared to said concentration of healthy control persons or patients with benign disease. This is especially true for patients with carcinoma of the pancreas (FIG. 1), significantly elevated concentrations were also determined in serum or plasma of patients with carcinoma of the stomach, colon or rectum. Equally good results were obtained irrespective of the conjugate system (antibody-peroxidase or WGA-peroxidase). With the use of MAb C as specific binding-component a sensitive test for tumor markers of especially gastrointestinal tumor disease can be made.
    • Example 5
  • Five μg each of MAb C or MAb C 50 as control (Pharmacia; Holmgren et al. (1984) British Med. J. 288, 1479) were pipetted in 50 μl phosphate-buffered-saline (PBS) into a CA 19-9 Test (CA 19-9 EIA “Roche”). The highest standard (100 U/ml) was added before start of the incubation. The tests were performed according to the instructions of the test-kit above and the absorbances of the respective samples were determined.
  • Result:
  • As shown in FIG. 2, the additional dilution of the standard-antigen after addition of the PBS-solution reduces the signal of the highest standard even without addition of MAb. No further reduction of the signal results by the presence of MAb C in the assay. In contrast hereto the signal formation is totally inhibited by MAb C 50, which as is known, binds among others specifically to the epitope “sialosyl Lea” recognized also by MAb 19-9: From the above one may conclude that MAb C recognizes a different epitope as MAb 19-9.

Claims (9)

1-16. (canceled)
17. A chimeric monoclonal antibody comprising variable VH and VK regions wherein said VH and VK regions comprise the amino acid sequences shown in FIG. 6 and in which the constant regions are human antibody amino acid sequences.
18. The monoclonal antibody as claimed in claim 17, wherein enzymes or radioactive labels are coupled to the antibody.
19. The monoclonal antibody as claimed in claim 17, wherein the antibody is coupled to toxins, catalytic antibodies, combinations of V genes of various specificities, MHC class I antigens or MHC class II antigens, or cytolytic components.
20. A pharmaceutical composition comprising the monoclonal antibody as claimed in claim 17 in a pharmaceutically acceptable carrier.
21. A monoclonal antibody as claimed in claim 17 for use in vivo or in vitro diagnosis.
22. A therapeutic composition comprising the antibody as claimed in claim 17 and an inert vehicle.
23. The monoclonal antibody as claimed in claim 17, wherein the variable regions have amino acid sequences shown in FIG. 6.
24. A method of producing the monoclonal antibody as claimed in claim 17 comprising:
(a) preparing DNA encoding said variable regions and said regions outside of the variable regions containing human antibody amino acid sequences and amplifying said DNA via polymerase chain reaction (PCR) using TAQ polymerase and PCR primers from cDNA isolated from hybridomas;
(b) expressing said DNA to produce said antibody; and
(c) isolating said antibody.
US10/942,929 1989-03-24 2004-09-17 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof Abandoned US20060159682A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/942,929 US20060159682A1 (en) 1989-03-24 2004-09-17 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof
US12/068,545 US7662383B2 (en) 1989-03-24 2008-02-07 Chimeric antibody against tumor associated antigens and its use in diagnosing tumors

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DEP3909799.4 1989-03-24
DE3909799A DE3909799A1 (en) 1989-03-24 1989-03-24 MONOCLONAL ANTIBODIES (MAK) AGAINST TUMOR ASSOCIATED ANTIGENS, THEIR PRODUCTION AND USE
US49720190A 1990-03-22 1990-03-22
US94935992A 1992-09-23 1992-09-23
US11878893A 1993-09-09 1993-09-09
US08/356,791 US6926896B2 (en) 1989-03-24 1994-12-13 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof
US10/942,929 US20060159682A1 (en) 1989-03-24 2004-09-17 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/356,791 Continuation US6926896B2 (en) 1989-03-24 1994-12-13 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/068,545 Continuation US7662383B2 (en) 1989-03-24 2008-02-07 Chimeric antibody against tumor associated antigens and its use in diagnosing tumors

Publications (1)

Publication Number Publication Date
US20060159682A1 true US20060159682A1 (en) 2006-07-20

Family

ID=6377161

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/356,791 Expired - Fee Related US6926896B2 (en) 1989-03-24 1994-12-13 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof
US10/942,929 Abandoned US20060159682A1 (en) 1989-03-24 2004-09-17 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof
US12/068,545 Expired - Fee Related US7662383B2 (en) 1989-03-24 2008-02-07 Chimeric antibody against tumor associated antigens and its use in diagnosing tumors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/356,791 Expired - Fee Related US6926896B2 (en) 1989-03-24 1994-12-13 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/068,545 Expired - Fee Related US7662383B2 (en) 1989-03-24 2008-02-07 Chimeric antibody against tumor associated antigens and its use in diagnosing tumors

Country Status (12)

Country Link
US (3) US6926896B2 (en)
EP (3) EP0727436B1 (en)
JP (1) JP3043772B2 (en)
KR (1) KR100189046B1 (en)
AT (3) ATE140486T1 (en)
AU (1) AU628948B2 (en)
CA (1) CA2012993C (en)
DE (4) DE3909799A1 (en)
DK (3) DK0388914T3 (en)
ES (3) ES2116790T3 (en)
GR (1) GR3020610T3 (en)
PT (1) PT93536B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03501209A (en) * 1988-05-17 1991-03-22 フェロン、ソルダノ Anti-idiotype antibody against anti-human high molecular weight melanoma-associated antigen
DE3909799A1 (en) * 1989-03-24 1990-09-27 Behringwerke Ag MONOCLONAL ANTIBODIES (MAK) AGAINST TUMOR ASSOCIATED ANTIGENS, THEIR PRODUCTION AND USE
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4106389A1 (en) * 1991-02-28 1992-09-03 Behringwerke Ag FUSION PROTEINS FOR PRODRUG ACTIVATION, THEIR PRODUCTION AND USE
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4033120A1 (en) * 1990-10-18 1992-04-23 Boehringer Mannheim Gmbh Genomic DNA fragment encoding antibody variable region prodn. - by attaching primers to hybridoma DNA then subjecting to polymerase chain reaction, for constructing genes encoding chimeric antibodies
DE4133791A1 (en) * 1991-10-11 1993-04-15 Behringwerke Ag MONOCLONAL ANTIBODIES AGAINST TUMOR ASSOCIATED ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
DE4225853A1 (en) * 1992-08-05 1994-02-10 Behringwerke Ag Granulocyte-binding antibody fragments, their production and use
US6030797A (en) * 1992-10-08 2000-02-29 Dade Behring Marburg Gmbh Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
MA24512A1 (en) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl PROCESS FOR THE PREPARATION OF ANTICOAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS
CA2420193A1 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
JP2011520914A (en) 2008-05-15 2011-07-21 トランスモレキュラー， インコーポレイテッド Treatment of metastatic tumor
IN2012DN01663A (en) * 2009-09-16 2015-06-05 Immunomedics Inc
JP5858932B2 (en) 2010-02-04 2016-02-10 モルフォテック， インコーポレイテッド Chlorotoxin polypeptides and conjugates and uses thereof
CN103097403B (en) 2010-05-11 2017-04-19 弗雷德哈钦森癌症研究中心 Chlorotoxin variants, conjugates, and methods for their use
WO2011144744A1 (en) 2010-05-20 2011-11-24 Therapharm Gmbh Targeted radioactive compound for human cd66 for the treatment of disorders
US20140179560A1 (en) 2012-12-10 2014-06-26 Fred Hutchinson Cancer Research Center Drug discovery methods and platforms
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
AU2017250359B2 (en) 2016-04-15 2022-06-16 Blaze Bioscience, Inc. Methods of treating breast cancer
EP3351271A1 (en) 2017-01-23 2018-07-25 TheraPharm GmbH Radioimmunoconjugate for use in treating bone marrow associated diseases

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4349528A (en) * 1979-11-21 1982-09-14 The Wistar Institute Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4446240A (en) * 1981-01-30 1984-05-01 Nerenberg Samuel T Pancreas specific protein systems
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4569788A (en) * 1983-05-18 1986-02-11 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies against non small cell lung cancer
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US4677058A (en) * 1983-05-19 1987-06-30 Karl Tryggvason Detecting malignant cells with monoclonal antibodies specific to type IV collagenase enzyme
US4683200A (en) * 1984-05-17 1987-07-28 Setsuo Hirohashi Monoclonal antibody to human cancer antigen and method for producing same
US5169939A (en) * 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5354847A (en) * 1986-10-27 1994-10-11 Bristol-Myers Squibb Company Chimeric antibody with specificity to human tumor antigen
US6926896B2 (en) * 1989-03-24 2005-08-09 Aventis Pharma Deutschland Gmbh Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1193378A (en) 1967-04-11 1970-05-28 Rand Dev Corp Cancer Antigen Complexes
JPH0811075B2 (en) 1982-06-30 1996-02-07 雄治 松岡 Monoclonal anti-CEA antibody
DE3483054D1 (en) 1983-03-04 1990-10-04 Health Research Inc MONOCLONAL ANTIBODIES AGAINST HUMAN BREAST CANCER CELLS AND THEIR USE IN DIAGNOSIS AND THERAPY.
DE3531301A1 (en) 1985-09-02 1987-03-05 Behringwerke Ag MONOCLONAL ANTIBODIES AGAINST TUMOR ASSOCIATED GLYCOPROTEINS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
US6294172B1 (en) * 1983-08-12 2001-09-25 Dade Behring Marburg Gmbh Monoclonal antibodies with specificity for membrane-associated antigens
DE3329184A1 (en) 1983-08-12 1985-02-21 Behringwerke Ag, 3550 Marburg MONOCLONAL ANTIBODIES WITH SPECIFICITY FOR MEMBRANE-ASSOCIATED ANTIGENS
DE3416774A1 (en) 1984-05-07 1985-11-14 Behringwerke Ag, 3550 Marburg MONOCLONAL ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
EP0145373B1 (en) * 1983-11-23 1992-03-25 The Ohio State University Research Foundation Purification of cancer-associated protein and preparation of antibody thereto
NZ210867A (en) 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
EP0160446B1 (en) 1984-05-01 1992-06-17 Ciba Corning Diagnostics Corp. Breast tumor-associated antigen and monoclonal antibodies specific thereto
JPS6144900A (en) * 1984-08-08 1986-03-04 Green Cross Corp:The Monoclonal antibody and reagent for detecting cancer antigen
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
CA1339798C (en) 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
AU617652B2 (en) * 1986-09-19 1991-12-05 Scripps Clinic And Research Foundation Monoclonal paratopic molecule directed to human ganglioside gd2
DK554886A (en) * 1986-11-19 1988-07-18 Novo Industri As ANTIBODIES
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
EP0365209A3 (en) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
DE68913658T3 (en) * 1988-11-11 2005-07-21 Stratagene, La Jolla Cloning of immunoglobulin sequences from the variable domains
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US4349528A (en) * 1979-11-21 1982-09-14 The Wistar Institute Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
US4446240A (en) * 1981-01-30 1984-05-01 Nerenberg Samuel T Pancreas specific protein systems
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4569788A (en) * 1983-05-18 1986-02-11 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies against non small cell lung cancer
US4677058A (en) * 1983-05-19 1987-06-30 Karl Tryggvason Detecting malignant cells with monoclonal antibodies specific to type IV collagenase enzyme
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US4683200A (en) * 1984-05-17 1987-07-28 Setsuo Hirohashi Monoclonal antibody to human cancer antigen and method for producing same
US5169939A (en) * 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US5354847A (en) * 1986-10-27 1994-10-11 Bristol-Myers Squibb Company Chimeric antibody with specificity to human tumor antigen
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US6926896B2 (en) * 1989-03-24 2005-08-09 Aventis Pharma Deutschland Gmbh Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

Also Published As

Publication number Publication date
DK0727435T3 (en) 1999-02-01
DK0727436T3 (en) 1999-02-01
ES2116789T3 (en) 1998-07-16
DE59010826D1 (en) 1998-07-09
ES2090052T3 (en) 1996-10-16
EP0388914B1 (en) 1996-07-17
ATE166883T1 (en) 1998-06-15
JPH032200A (en) 1991-01-08
EP0727436A1 (en) 1996-08-21
DE59010418D1 (en) 1996-08-22
DE3909799A1 (en) 1990-09-27
DK0388914T3 (en) 1996-11-04
EP0727435A1 (en) 1996-08-21
ES2116790T3 (en) 1998-07-16
JP3043772B2 (en) 2000-05-22
EP0727435B1 (en) 1998-06-03
GR3020610T3 (en) 1996-10-31
CA2012993A1 (en) 1990-09-24
CA2012993C (en) 2001-07-03
EP0727436B1 (en) 1998-06-03
PT93536A (en) 1990-11-07
US20090246132A1 (en) 2009-10-01
KR900013986A (en) 1990-10-22
ATE140486T1 (en) 1996-08-15
US20020068056A1 (en) 2002-06-06
ATE166882T1 (en) 1998-06-15
AU5215090A (en) 1990-11-08
AU628948B2 (en) 1992-09-24
EP0388914A1 (en) 1990-09-26
DE59010825D1 (en) 1998-07-09
PT93536B (en) 1996-03-29
US7662383B2 (en) 2010-02-16
KR100189046B1 (en) 1999-06-01
US6926896B2 (en) 2005-08-09

Similar Documents

Publication Publication Date Title
US7662383B2 (en) Chimeric antibody against tumor associated antigens and its use in diagnosing tumors
EP0783313B1 (en) Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies
US6071515A (en) Dimer and multimer forms of single chain polypeptides
US20060246077A1 (en) Use of antibodies against the MUC18 antigen
WO2004081051A1 (en) Bispecific antibodies
JP2022130744A (en) Use of anti-her2 antibody-drug conjugates in treatment of urothelial carcinoma
Xu et al. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells
US7384631B2 (en) Methods of diagnosis and treatment by binding p75/AIRM1
WO1998012227A1 (en) Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
EP1175227B1 (en) Monoclonal antibody directed against cells of human renal cell carcinoma
AU723073B2 (en) CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AU689331C (en) CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
CN118184785A (en) CEA antibodies and uses thereof
CN118324916A (en) Monoclonal antibody for resisting human GPRC5D, and preparation method and application thereof
Colnaghi et al. Monoclonal Antibodies in Diagnosis, Prognosis, and Therapy of Human Carcinomas: Clinical Impact 20 Years Later

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载